p21 disrupts the interaction between cdk2 and the E2F-p130 complex

被引:0
|
作者
Shiyanov, P
Bagchi, S
Adami, G
Kokontis, J
Hay, N
Arroyo, M
Morozov, A
Raychaudhuri, P
机构
[1] UNIV ILLINOIS,DEPT BIOCHEM,CHICAGO,IL 60612
[2] UNIV ILLINOIS,COLL DENT,CHICAGO,IL 60612
[3] UNIV CHICAGO,BEN MAY INST,DEPT PHARMACOL & PHYSIOL SCI,CHICAGO,IL 60637
关键词
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In nonproliferating or growth-arrested cells, the transcription factor E2F remains bound to the retinoblastoma-related protein p130. Accumulation of this E2F-p130 complex correlates with an arrest of the cell cycle progression. Progression through G(1) phase is associated with a cyclin-dependent binding of the cyclin-dependent kinase cdk2 to the E2F-p130 complex. By fractionating mouse L-cell extracts, we have obtained a partially purified preparation of the E2F-p130 complex that also contains cdk2. Incubation of this complex with recombinant p21 results in a disruption of the interaction between cdk2 and the E2F-p130 complex. We have also analyzed the interaction between cdk2 and the E2F-p130 complex in extracts of a cell line that expresses a temperature-sensitive mutant of p53. Incubation at the permissive temperature (32 degrees C) results in an induction of p21 synthesis. An increase in the level of p21 in these cells correlates with a loss of cdk2 from the cdk2-containing E2F-p130 complex. We also show that the expression of a reporter gene containing E2F sites in the promoter region is reduced by the coexpression of p21. Since p21 is believed to be a mediator of p53, we speculate that the p21-mediated disruption of the cdk2-containing E2F-p130 complex plays a role in the growth suppression function of p53.
引用
收藏
页码:737 / 744
页数:8
相关论文
共 50 条
  • [41] Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution
    PlanasSilva, MD
    Weinberg, RA
    MOLECULAR AND CELLULAR BIOLOGY, 1997, 17 (07) : 4059 - 4069
  • [42] A unique domain of pRb2/p130 acts as an inhibitor of Cdk2 kinase activity
    DeLuca, A
    MacLachlan, TK
    Bagella, L
    Dean, C
    Howard, CM
    Claudio, PP
    Baldi, A
    Khalili, K
    Giordano, A
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (34) : 20971 - 20974
  • [43] The association of cyclin A and cyclin kinase inhibitor p21 in response to γ-irradiation requires the CDK2 binding region, but not the Cy motif
    Fukuchi, K
    Nakamura, K
    Ichimura, S
    Tatsumi, K
    Gomi, K
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2003, 1642 (03): : 163 - 171
  • [44] The CDK2 phosphorylation site on ID2 regulates myod-induced expression of the troponin I and p21 promoters.
    Lobe, DR
    Matsumura, ME
    McNamara, CA
    FASEB JOURNAL, 1999, 13 (04): : A196 - A196
  • [45] Mechanism of Cdk2/cyclin E inhibition by p27 and p27 phosphorylation
    Xu, X
    Nakano, T
    Wick, S
    Dubay, M
    Brizuela, L
    BIOCHEMISTRY, 1999, 38 (27) : 8713 - 8722
  • [46] Clinical CDK4/6 inhibitors induce selective and immediate dissociation of p21 from cyclin D-CDK4 to inhibit CDK2
    Pack, Lindsey R.
    Daigh, Leighton H.
    Chung, Mingyu
    Meyer, Tobias
    NATURE COMMUNICATIONS, 2021, 12 (01)
  • [47] Clinical CDK4/6 inhibitors induce selective and immediate dissociation of p21 from cyclin D-CDK4 to inhibit CDK2
    Lindsey R. Pack
    Leighton H. Daigh
    Mingyu Chung
    Tobias Meyer
    Nature Communications, 12
  • [48] The Speedy A, Cdk2, p27 triangle
    Dewhurst, Matthew R.
    Kaldis, Philipp
    CELL CYCLE, 2016, 15 (04) : 489 - 490
  • [49] p53 and p21 form an inducible barrier that protects cells against cyclin E-cdk2 deregulation
    Minella, AC
    Swanger, J
    Bryant, E
    Welcker, M
    Hwang, H
    Clurman, BE
    CURRENT BIOLOGY, 2002, 12 (21) : 1817 - 1827
  • [50] Activation of AMPK Attenuated Cardiac Fibrosis by Inhibiting CDK2 via p21/p27 and miR-29 Family Pathways in Rats
    Qi, Hanping
    Liu, Yan
    Li, Shuzhi
    Chen, Yunping
    Li, Lei
    Cao, Yonggang
    E, Mingyao
    Shi, Pilong
    Song, Chao
    Li, Baiyan
    Sun, Hongli
    MOLECULAR THERAPY-NUCLEIC ACIDS, 2017, 8 : 277 - 290